Advanced Biodesign

Executive Summary

Advanced Biodesign is a French private biotech company focused on overcoming cancer drug resistance through small molecule therapeutics. Founded in 2010 and headquartered in Paris, the company operates at the pre-clinical stage with no disclosed funding rounds or valuation. Despite limited public information, its specialization in addressing a critical oncology challenge positions it within a high-need area. The company's lack of pipeline visibility and early-stage profile suggest significant risk but also potential for value creation if key milestones are achieved. Its long history of development without clinical entry may indicate a focused, research-oriented strategy or financing constraints.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program40% success
• Q3 2026Preclinical Proof-of-Concept Data Release50% success
• Q3 2026Collaboration or Licensing Agreement30% success